Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
|Articles|July 18, 2022
Achieving Full Collections: Why Revenue Cycle Management is Key to Practice Success
Advertisement
With everything going on in the economy, managing the nitty gritty of your practice is one of the last headaches a physician needs to deal with. Between staffing shortages and rising costs, practices need a leading-edge solution.
Revenue Cycle Management (RCM) eliminates variability from staff turnover, and in turn increases the accountability and reliability of your practice. Download this whitepaper to learn more about which unique RCM system is the right fit for your practice.
Fill out the form below to download the whitepaper:
Sponsored by:
Advertisement
Related to this article
Learn when your baby is ready for solids, choose safe purees or finger foods, prevent choking, prioritize iron, and introduce allergens confidently.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
FDA approval of Gazyva offers new option for pediatric INS
3
DTaP 96% effective against pertussis in Alaska outbreak
4
FDA grants Cinainu Breakthrough Therapy status for pediatric AA
5